17-Aug-2026
Market Chameleon (Thu, 23-Jul 6:29 AM ET)
Novocure's Record Quarter: Patient Growth and Margin Expansion Highlight Positive Momentum
Market Chameleon (Thu, 23-Jul 3:30 AM ET)
Novocure Reports Second Quarter 2026 Financial Results
Business Wire (Thu, 23-Jul 7:00 AM ET)
Globe Newswire (Tue, 14-Jul 6:24 PM ET)
Novocure to Report Second Quarter 2026 Financial Results
Business Wire (Wed, 1-Jul 7:00 AM ET)
Novocure's Optune Pax Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
Business Wire (Tue, 30-Jun 7:00 AM ET)
Business Wire (Sat, 20-Jun 1:34 PM ET)
PRNewswire (Thu, 18-Jun 9:41 PM ET)
Business Wire (Thu, 18-Jun 7:00 AM ET)
Novocure Revenue Grows 12% on Global Patient Expansion; New Device Approvals Mark Milestone Quarter
Market Chameleon (Thu, 30-Apr 7:06 AM ET)
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Novocure Limited - trades on the NASDAQ stock market under the symbol NVCR.
As of August 17, 2026, NVCR stock price climbed to $17.53 with 996,175 million shares trading.
NVCR has a beta of 1.47, meaning it tends to be more sensitive to market movements. NVCR has a correlation of 0.07 to the broad based SPY ETF.
NVCR has a market cap of $2.04 billion. This is considered a Mid Cap stock.
Last quarter Novocure Limited - reported $184 million in Revenue and -$.13 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.20.
In the last 3 years, NVCR traded as high as $34.13 and as low as $9.82.
The top ETF exchange traded funds that NVCR belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.
NVCR has outperformed the market in the last year with a price return of +51.3% while the SPY ETF gained +21.0%. However, in the short term, NVCR had mixed performance relative to the market. It has underperformed in the last 3 months, returning -2.9% vs +3.5% return in SPY. But in the last 2 weeks, NVCR shares have fared better than the market returning +18.1% compared to SPY +3.4%.
NVCR support price is $16.37 and resistance is $17.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVCR shares will trade within this expected range on the day.
